Brooks Kuhn, MD, MAS

Equivalent efficacy with fewer infusions would already improve patients' lives, while a superior effect on lung loss or exacerbations would change the treatment threshold. The panel outlines what data would support either outcome.

Phase 2 data show recombinant AAT-Fc therapy restoring normal functional levels with far fewer infusions than plasma-derived augmentation. Whether those levels translate to clinical benefit will depend on longer studies.

An engineered Fc fusion protein is designed to circulate longer, resist oxidation, and hold levels within the true normal range between infusions, without depending on human plasma.

No trial has shown a significant FEV1 benefit, yet FEV1 may be the wrong yardstick for emphysema. CT densitometry and real-world comparisons support augmentation, while testing and liver coordination remain unmet needs.

Fewer than two-thirds of patients prescribed augmentation begin infusions, and half of starters miss doses. Structured education lifts adherence sharply, while plasma supply and partial coverage expose the limits of current therapy.

Weekly dosing produces high early levels and a falling trough. Panelists explain how they balance exacerbations, travel, and infusion access, and why they discourage routine level monitoring once therapy begins.

The 11 micromolar target was built on epidemiologic reasoning rather than a normal range. Pending trials of higher doses and longer-acting agents may show whether raising levels further improves outcomes.

Four plasma-derived products deliver the same purified protein and appear clinically interchangeable. Differences in formulation, administration, and coverage design shape which product a patient actually receives.

Cost data in AATD depend heavily on how patients are identified. Augmentation therapy adds a substantial burden, yet survival benefit and comorbidity management complicate any simple cost comparison for payers.

Clinicians cannot be expected to remember every rare disease. Default order sets, testing tied to pulmonary function results, and standardized genotyping can make AATD testing the easy choice rather than an added burden.

The same AAT level can mean very different protease burdens in two patients. Severe deficiency drives the highest risk, yet carriers and unusual alleles complicate any simple relationship between numbers and disease.

Decades of guidelines have recommended testing every patient with COPD, yet testing remains rare. The panel examines who gets missed, why clinicians believe they can spot AATD, and what health plans can do.

A serum level is a snapshot, while genotype is the blueprint. Relying on levels alone misses carriers and mislabels patients, and the resulting diagnostic gap carries real clinical and economic costs.

AATD is better understood as a genetic predisposition than a single disease. Genotype, codominant inheritance, and environmental exposure together shape who develops lung or liver disease and how severe it becomes.